Form 8.3 - Lok’n Store Group PLC
June 05, 2024 10:17 ET
|
Rathbones Group PLC
7276118.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Compass Minerals International
June 05, 2024 10:15 ET
|
Faruqi & Faruqi LLP
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Compass Minerals International, Inc. (“Compass...
Johnson & Johnson presenta a la Agencia Europea de Medicamentos una solicitud de aprobación de la formulación subcutánea de RYBREVANT®▼ (amivantamab) para el tratamiento de pacientes con cáncer de pulmón no microcítico con mutación del EGFR
June 05, 2024 10:14 ET
|
Janssen Cilag International NV
La solicitud está respaldada por los datos del estudio de fase 3 PALOMA-3 presentado en la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO)1 La nueva formulación demostró no ser...
HighCo: shareholding as 05/31/2024
June 05, 2024 10:14 ET
|
HIGHCO
INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES Declaration pursuant to Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité...
Form 8.3 - Equals Group PLC
June 05, 2024 10:13 ET
|
Downing LLP
Downing LLPLEI: 213800G3X76VBG9SB50405 June 2024Form 8.3 re. Equals Group Plc PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1%...
Form 8.3 - Keywords Studios Plc
June 05, 2024 10:13 ET
|
Rathbones Group PLC
8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY...
Johnson & Johnson soumet à l’Agence européenne des médicaments une demande d’approbation de la formulation sous-cutanée de RYBREVANT®▼ (amivantamab) pour le traitement des patients atteints d’un cancer du poumon non à petites cellules avec mutation de l’EGFR
June 05, 2024 10:12 ET
|
Janssen Cilag International NV
La demande est étayée par les données de l’étude de Phase III PALOMA-3 présentées lors de la réunion annuelle de l’American Society of Clinical Oncology (« ASCO »)1 La nouvelle formulation a montré...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines – CORBF
June 05, 2024 10:12 ET
|
Pomerantz LLP
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Global Cord Blood Corporation (“Global Cord” or the “Company”) (OTC: CORBF) and...
Form 8.3 - Crimson Tide Plc
June 05, 2024 10:09 ET
|
Rathbones Group PLC
8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in VinFast Auto Ltd. of Class Action Lawsuit and Upcoming Deadlines – VFS
June 05, 2024 10:07 ET
|
Pomerantz LLP
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against VinFast Auto Ltd. (“VinFast” or the “Company”) f/k/a Black Spade Acquisition...